In this issue:
Anti-TNF-α and cancer in IBD, rheumatoid arthritis and psoriasis
Adherence to therapy in pregnant women with IBD
HLADQA1*05 genotype and infliximab response
Longitudinal trends in IBD costs and healthcare utilisation
Dupilumab for active eosinophilic oesophagitis
TNF antagonists for internal fistulising CD
Clinical decision support tool to optimise vedolizumab therapy in CD
Elective switching to vedolizumab in IBD patients in remission
Speed of onset of action of infliximab vs golimumab in UC
Serious infections with biologic/immunosuppressive therapy for IBD
Please login below to download this issue (PDF)